AC-170 0.24%

DRUG5 trials

Sponsors

Aciex Therapeutics, Inc., Nicox Ophthalmics, Inc.

Conditions

Allergic ConjunctivitisHealthy Subjects

Phase 2

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

CompletedNCT01332188

Aciex Therapeutics, Inc.Allergic Conjunctivitis

Start: 2011-04-30End: 2011-10-31Updated: 2017-08-30

Phase 3

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

CompletedNCT01551056

Aciex Therapeutics, Inc.Allergic Conjunctivitis

Start: 2012-03-31End: 2012-06-30Updated: 2017-11-07

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

CompletedNCT01685242

Aciex Therapeutics, Inc.Allergic Conjunctivitis

Start: 2012-09-30End: 2012-11-30Updated: 2017-10-10

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

CompletedNCT01881113

Aciex Therapeutics, Inc.Allergic Conjunctivitis

Start: 2013-06-30End: 2013-10-31Updated: 2017-11-09

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

CompletedNCT02756624

Nicox Ophthalmics, Inc.Healthy Subjects

Start: 2016-04-30End: 2016-08-31Updated: 2017-09-11